These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38740304)

  • 41. Microbiological findings in burn patients treated in a general versus a designated intensive care unit: Effect on length of stay.
    Issler-Fisher AC; Fakin RM; Fisher OM; McKew G; Gazzola R; Rauch AK; Gottlieb T; Haertsch P; Guggenheim M; Giovanoli P; Maitz PK
    Burns; 2016 Dec; 42(8):1805-1818. PubMed ID: 27372144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
    Torres-Gonzalez P; Cervera-Hernandez ME; Niembro-Ortega MD; Leal-Vega F; Cruz-Hervert LP; García-García L; Galindo-Fraga A; Martinez-Gamboa A; Bobadilla-Del Valle M; Sifuentes-Osornio J; Ponce-de-Leon A
    PLoS One; 2015; 10(10):e0139883. PubMed ID: 26431402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
    Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
    Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
    Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
    Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Carbapenem-resistant Enterobacteriaceae in patients admitted to the emergency department: prevalence, risk factors, and acquisition rate.
    Salomão MC; Guimarães T; Duailibi DF; Perondi MBM; Letaif LSH; Montal AC; Rossi F; Cury AP; Duarte AJS; Levin AS; Boszczowski I
    J Hosp Infect; 2017 Nov; 97(3):241-246. PubMed ID: 28826688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patterns of multidrug resistant organism acquisition in an adult specialist burns service: a retrospective review.
    Cleland H; Tracy LM; Padiglione A; Stewardson AJ
    Antimicrob Resist Infect Control; 2022 Jun; 11(1):82. PubMed ID: 35698209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP
    Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
    Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
    Li C; Li Y; Zhao Z; Liu Q; Li B
    J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intestinal Dysbiosis in Carriers of Carbapenem-Resistant
    Korach-Rechtman H; Hreish M; Fried C; Gerassy-Vainberg S; Azzam ZS; Kashi Y; Berger G
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32350099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Epidemiology and risk factors for carbapenem-resistant Enterobacteriaceae colonisation and infections: case-controlled study from an academic medical center in a southern area of China.
    Fang L; Lu X; Xu H; Ma X; Chen Y; Liu Y; Hong G; Liang X
    Pathog Dis; 2019 Jun; 77(4):. PubMed ID: 31281931
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk Factors for Carbapenem-Resistant
    Rebold N; Lagnf AM; Alosaimy S; Holger DJ; Witucki P; Mannino A; Dierker M; Lucas K; Kunz Coyne AJ; El Ghali A; Caniff KE; Veve MP; Rybak MJ
    Microbiol Spectr; 2023 Feb; 11(1):e0264722. PubMed ID: 36622246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Carbapenem-resistant Enterobacteriaceae among kidney transplant recipients - insights on the risk of acquisition and CRE infection.
    Freire MP; Carvalho LB; Reusing JO; Spadão F; Lopes MIBF; Nahas WC; David-Neto E; Pierrotti LC
    Infect Dis (Lond); 2021 Jun; 53(6):430-439. PubMed ID: 33612056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity.
    Swaminathan M; Sharma S; Poliansky Blash S; Patel G; Banach DB; Phillips M; LaBombardi V; Anderson KF; Kitchel B; Srinivasan A; Calfee DP
    Infect Control Hosp Epidemiol; 2013 Aug; 34(8):809-17. PubMed ID: 23838221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical characteristics and risk factors for neonatal bloodstream infection due to carbapenem-resistant Enterobacteriaceae: A single-centre Chinese retrospective study.
    Fang P; Gao K; Yang J; Li T; Sun Q; Shan Z; Wang Y
    J Glob Antimicrob Resist; 2024 Jun; 37():28-36. PubMed ID: 38412919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Carbapenem-resistant enterobacteriaceae screening: A core infection control measure for critical care unit in India?
    Ramanathan YV; Venkatasubramanian R; Nambi PS; Ramabathiran M; Venkataraman R; Thirunarayan MA; Samundeeswari P; Ramakrishnan N
    Indian J Med Microbiol; 2018; 36(4):572-576. PubMed ID: 30880709
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case-control study.
    Teo J; Cai Y; Tang S; Lee W; Tan TY; Tan TT; Kwa AL
    PLoS One; 2012; 7(3):e34254. PubMed ID: 22461908
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
    Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk factors for outbreaks of multidrug-resistant Klebsiella pneumoniae in critical burn patients.
    Sánchez M; Herruzo R; Marbán A; Araujo P; Asensio MJ; Leyva F; Casado C; García-de-Lorenzo A
    J Burn Care Res; 2012; 33(3):386-92. PubMed ID: 21979841
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.
    Nicolas-Chanoine MH; Vigan M; Laouénan C; Robert J;
    Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):383-393. PubMed ID: 30488368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.